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REPLY
We thank Drs. Taylor-Robinson and Thomas for their interest in
our study, which found circulating Chlamydia pneumoniae (C.
pneumoniae) DNA to be associated with coronary artery disease
(CAD) in men but not women (1). The association in men was
moderate, with an odds ratio of 3.2 (95% confidence interval 1.1 to
8.9), and this was stronger than that reported in most serologic
studies (2). We discussed possible reasons for the lack of an
association in women, but because the number of male subjects was
over twice that of females, the statistical power to detect a
difference was strongest for men. In our study, patients and control
subjects were defined according to the presence of CAD by
angiographic criteria, an approach taken by other studies of C.
pneumoniae and CAD (2), and, indeed, by studies that have
investigated other coronary risk factors. We can justifiably claim
that we have found an association between C. pneumoniae DNA
and clinically significant atherosclerosis.
Our study and that of Boman et al. (3) are still the only
published reports on circulating C. pneumoniae DNA and CAD,
and we pointed out the differences in the reported prevalence of C.
pneumoniae DNA. In our view, the finding that circulating C.
pneumoniae DNA was found in 46% of a healthy, blood-donating
population (3) is remarkable and an extraordinarily high level for
any bacterium. However, although our study was far larger than
Boman’s, further work is required to clarify the situation, but we
cannot comment on the unpublished data of the correspondents or
their observations.
It would be generally accepted that evidence of current C.
pneumoniae infection should be found before prescribing antibiot-
ics to patients with CAD. At present, the presence of circulating
C. pneumoniae DNA is the most accurate method of diagnosing
current infection and is therefore a means of identifying suitable
patients for intervention trials. This was also a view held by the
correspondents (4), and we are therefore surprised by their state-
ment that “fortunately,” current antibiotic trials are being under-
taken with complete disregard for the PBMC C. pneumoniae
status. Fortunately, investigators running such trials do realize the
potential importance of such a test (5).
Yuk-ki Wong
Wessex Cardiothoracic Unit
Southampton General Hospital
Tremona Road
Southampton, Hampshire S016 6YD
United Kingdom
Keith D. Dawkins
Michael E. Ward
PII S0735-1097(00)00764-6
REFERENCES
1. Wong Y, Dawkins KD, Ward ME. Circulating Chlamydia pneumoniae
DNA as a predictor of coronary artery disease. J Am Coll Cardiol
1999;34:1435–9.
2. Wong YK, Gallagher PJ, Ward ME. Chlamydia pneumoniae and
atherosclerosis. Heart 1999;81:232–8.
3. Boman J, Soderberg S, Forsberg J, et al. High prevalence of Chlamydia
pneumoniae DNA in peripheral blood mononuclear cells in patients with
cardiovascular disease and in middle-aged blood donors. J Infect Dis
1998;178:274–7.
4. Taylor-Robinson D, Thomas BJ. Chlamydia pneumoniae in arteries: the
facts, their interpretation, and future studies. J Clin Pathol 1998;51:
793–7.
5. Grayston JT, Jackson LA, Kennedy WJ, et al. Secondary prevention
trials for coronary artery disease with antibiotic treatment for Chlamydia
pneumoniae: design issues. Am Heart J 1999;138:S545–9.
The Electric Cardiographic
Abnormalities Are Not Hidden!
The report by Matetzky et al. (1) stimulates the following
thoughts. There are two ways to interpret electrocardiograms
(ECGs). One is to memorize patterns and the other is to use basic
principles of electrocardiography, including the use of vector
concepts, as described by Grant (2–6).
The tracing in Figure 1A of the report by Matetzky et al. reveals
a left atrial abnormality; a mean spatial QRS vector that is directed
at about 120° in the frontal plane (it changes direction during
inspiration and expiration) and about 45° posteriorly; a mean
spatial ST segment vector that is directed at 1115° in the frontal
plane and at least 90° posteriorly, indicating epicardial injury of the
posterior wall of the left ventricle; a mean spatial T-wave vector
that is directed at 190° in the frontal plane and 80° to 90°
anteriorly, indicating posterior myocardial ischemia; and a large U
wave in lead I.
The point is, the ST segment vector points toward an area of
posterior epicardial injury. Furthermore, one can suspect that the
ST segment vector is directed toward an obstruction in the
circumflex coronary artery or its branches. It should be no surprise
that the ST segment is elevated in leads V7–9, because the
transitional pathway was just beyond electrode position V6. The ST
segment abnormality is not hidden.
The follow-up discharge tracing in Figure 1B is also interesting.
The left atrial abnormality has disappeared; an S1, S2 and S3
conduction defect has developed; and the first half of the QRS
complex is directed at about 140° in the frontal plane and
markedly anterior, producing large abnormal R waves in leads V1
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